AN2 Therapeutics Beheer
Beheer criteriumcontroles 3/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Eric Easom
Algemeen directeur
US$3.3m
Totale compensatie
| Percentage CEO-salaris | 17.2% |
| Dienstverband CEO | 5yrs |
| Eigendom CEO | 4.1% |
| Management gemiddelde ambtstermijn | 5yrs |
| Gemiddelde ambtstermijn bestuur | 4.8yrs |
Recente managementupdates
Recent updates
Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?
Jul 04
Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Mar 23AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Dec 05AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Aug 20We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
May 09We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Feb 03We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely
Oct 21AN2 Therapeutics secures $17.8M contract from NIH
Sep 29We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
Jul 01Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$65m |
| Mar 31 2024 | n/a | n/a | -US$66m |
| Dec 31 2023 | US$3m | US$575k | -US$65m |
| Sep 30 2023 | n/a | n/a | -US$60m |
| Jun 30 2023 | n/a | n/a | -US$54m |
| Mar 31 2023 | n/a | n/a | -US$49m |
| Dec 31 2022 | US$3m | US$481k | -US$43m |
| Sep 30 2022 | n/a | n/a | -US$40m |
| Jun 30 2022 | n/a | n/a | -US$38m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$2m | US$377k | -US$28m |
Compensatie versus markt: De totale vergoeding ($USD 3.34M ) Eric } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 653.16K ).
Compensatie versus inkomsten: De vergoeding van Eric is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Eric Easom (56 yo)
5yrs
Tenure
US$3,342,848
Compensatie
Mr. Eric E. Easom is Co-founder of AN2 Therapeutics, Inc. and has been its CEO, President & Director from November 19, 2019 and is its Chairman of the Board since June 2024. He served as Senior Director of...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 5yrs | US$3.34m | 4.06% $ 1.3m | |
| Co-Founder & Chairman of the Board | 7.5yrs | US$179.64k | 1.69% $ 554.5k | |
| CFO, Principal Financial Officer & Principal Accounting Officer | 5yrs | US$1.52m | 0.010% $ 3.4k | |
| Co-Founder & Senior Clinical Advisor | no data | geen gegevens | geen gegevens | |
| Co-Founder & Head of Biology | no data | geen gegevens | geen gegevens | |
| Chief Legal Officer & Secretary | 2.2yrs | US$1.66m | geen gegevens | |
| Chief Development Officer | 5yrs | geen gegevens | 0.0025% $ 807.5 |
5.0yrs
Gemiddelde duur
60.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ANTX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 5yrs | US$3.34m | 4.06% $ 1.3m | |
| Co-Founder & Chairman of the Board | 7.5yrs | US$179.64k | 1.69% $ 554.5k | |
| Independent Director | 2.8yrs | US$145.64k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$153.14k | 0% $ 0 | |
| Lead Independent Director | 2.5yrs | US$142.14k | 0% $ 0 | |
| Independent Director | 5yrs | US$146.14k | 0% $ 0 | |
| Independent Director | 3.6yrs | US$157.14k | 0% $ 0 | |
| Independent Director | 5yrs | US$145.64k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$145.64k | 0.076% $ 25.1k |
4.8yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ANTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).